Megan Loy

Global Dyslipidemia Therapy Area Lead

SEP 2021 - NOV 2024 · 3.3 years

Commanded the strategic vision and operational implementation of the Dyslipidemia portfolio valued at >500M€. Senior Leader of the global brand team, leading a global team of 5 and accountable for a budget of 8M€. Achieved +17.2M€ net sales over baseline and secured 3.9M€ for data generation, analytics, tactics and messaging initiatives.

Global Medical Lead - Praluent®

NOV 2020 - SEP 2021 · 11 months

Directed global medical affairs strategy and operations for Praluent, overseeing insights generation, tactical implementation, execution, and accountability. Partnered with European Atherosclerosis Society to design digital risk calculator and led Global COVID-19 Cardiovascular Taskforce.

Global Medical Director Cardiovascular

MAR 2019 - NOV 2020 · 1.8 years

Led worldwide medical data generation initiatives for Praluent and implemented the global medical plan in diverse regions. Joint Medical Affairs Alliance Committee Chair responsible for strategic allocation of >10M€ in study funding. Secured regulatory approvals in US, EU and China.

Medical Manager Cardiovascular

SEP 2016 - FEB 2019 · 2.5 years

CV medical expert delivering the strategic medical plan with a budget of $1M and leading a team of 4 nationwide. Implemented post-trial access program for >100 eligible patients and presented to Australian Minister for Health on CV model of care solutions.

Medical Science Liaison, Diabetes and Cardiovascular

AUG 2015 - SEP 2016 · 1.2 years

Responsible for stakeholders' comprehension of key clinical data and advocacy for new therapies. Established partnerships with research institutes to educate >500 clinicians and forged network of >400 healthcare professionals through medical education initiatives.